ABBV · News · 20261103N

Guidance / Outlook

AbbVie Inc. · 2026-11-03 · Importance 43 · Surprise 60

A November 3, 2026 report said AbbVie raised its guidance following its third-quarter results. The report does not provide the revised guidance figures, the prior outlook, or the timeframe covered. It also cites growth in Skyrizi and Rinvoq, but gives no quantified outlook impact.

Key facts